Published in final edited form as:

Metabolism. 2010 September ; 59(9): 1365–1371. doi:10.1016/j.metabol.2009.12.023.

Endothelial Function in Individuals with Coronary Artery Disease with and without Type 2 Diabetes

Gisette Reyes-Soffer¹, Steve Holleran², Marco R. Di Tullio⁴, Shunichi Homma⁴, Bernadette Boden-Albala³, Rajasekhar Ramakrishnan², Mitchell S. Elkind³, Ralph L. Sacco³, and Henry N. Ginsberg¹

¹ Department of Medicine, Columbia University, Medical Center, New York, NY

² Department of Pediatrics, Columbia University, Medical Center, New York, NY

³ Department of Neurology, Columbia University, Medical Center, New York, NY

⁴ Department of Cardiology, Columbia University, Medical Center, New York, NY

Abstract

Aim and Hypothesis—The goal of this study was to determine if individuals with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) had greater endothelial dysfunction (ED) than individuals with only CAD.

Methods—Flow mediated dilation (FMD), calculated as percentage increase in brachial artery diameter in response to post-ischemic blood flow, was measured after an overnight fast in two cohorts. The first cohort included 76 participants in the Northern Manhattan Study (NOMAS) with CAD; 25 also had T2DM. The second cohort was composed of 27 individuals with both T2DM and CAD who were participants in a study of postprandial lipemia. Combined, we analyzed 103 patients with CAD; 52 with T2DM (T2DM+) and 51 without T2DM (T2DM–).

Results—The 52 CAD T2DM+ subjects had a mean FMD of $3.9 \pm 3.2\%$, while the 51 CAD T2DM– subjects had a greater mean FMD of $5.5 \pm 4.0\%$ ($P < 0.03$). An investigating of various confounders known to affect FMD identified age and BMI as the only significant covariates in a multiple regression model. Adjusting for age and BMI, we found that FMD remained lower in T2DM+ subjects compared to T2DM– subjects (difference -1.99% , $P < 0.03$).

Interpretation/Conclusion—In patients with CAD, the concomitant presence of T2DM is independently associated with greater ED, as measured by FMD. This finding may be relevant to the greater early and late morbidity and mortality observed in patients with both CAD and T2DM.

Keywords

Diabetes; CAD; Endothelial Function; Flow-Mediated Dilation

Corresponding Author: Henry N. Ginsberg, MD, Columbia University Medical Center, 632 West 168th Street, PH-10-305, NY, NY 10032, 212-305-9562 (phone), 212-305-3213 (fax), hng1@columbia.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) are closely linked, at least in part via concomitant risk factors that often manifest prior to the onset of T2DM.¹ Although the severity of CVD risk varies among diabetics of different ages and duration of disease, many patients have enough risk that T2DM has been considered to be a risk equivalent of coronary artery disease (CAD).^{2,3} The basis for the increase in CVD risk in patients with T2DM is multi-factorial, and may include the accumulation of glycated end products, cellular oxidative stress, and impaired production of nitric oxide.⁴ Increased levels of inflammatory cytokines and soluble integrins, such as s-ICAM and s-VCAM, are also present in individuals with T2DM and may contribute to a higher risk for CVD.^{5,6}

Endothelial dysfunction (ED) is a key early event in the development of atherosclerosis^{7–9} and can be demonstrated prior to the onset of overt CVD.^{10–12} ED is found in people with insulin resistance and may be a link between T2DM, in which insulin resistance plays a central role and CVD.^{13,14} Indeed, ED can predict the future onset of T2DM.¹⁵ ED can be demonstrated in individuals with either type 1 diabetes mellitus^{16,17} or T2DM.^{18–20}

In humans, endothelial function can be tested non-invasively using echocardiographic methods to measure flow mediated dilation (FMD) of the brachial artery.^{21–23} FMD of the brachial artery correlates negatively with ED in the coronary arteries.^{24,25} Several studies have shown that FMD is abnormal in patients with coronary artery disease (CAD),^{26,27} and correlates negatively with extent of CAD.^{28,29} Importantly, FMD also predicts future CVD events in healthy populations^{11,30,31} as well as long-term outcomes in people who have had CAD events.^{32–34} There are few studies, however, that have examined FMD in people with both CAD and T2DM.^{35,36} Since both CAD and T2DM are associated with ED, the question of whether ED is even greater in individuals with both CAD and T2DM is an important one, particularly in view of the clear demonstration of greater early and late morbidity and mortality in people with T2DM who have had a coronary event.^{37,38} Therefore, we assessed FMD in people with CAD, either with T2DM (T2DM+) or without T2DM (T2DM–). Our goal was to determine if individuals diagnosed with CAD and T2DM had a greater degree of ED than people with only CAD.

METHODS

Subjects

We enrolled 103 subjects from two cohorts. All subjects signed a consent form and the studies were approved by the Columbia University Medical Center (CUMC) Institutional Review Board. One cohort was composed of 76 subjects from the Northern Manhattan Study (NOMAS).^{39,40} In brief, NOMAS is a multi-ethnic population-based prospective cohort study that examines risk factors for cerebrovascular disease. In NOMAS there were 76 participants with FMD data who had CAD (diagnosed by self-report or documented history of myocardial infarction): 25 of the 76 also had T2DM [diagnosed by presence of fasting plasma glucose (FPG) level >126mg/dl, subjects' self report, use of insulin or other hypoglycemic medications]. The other 51 NOMAS subjects with CAD did not have T2DM. The second cohort was obtained from a study of postprandial lipemia in T2DM (DMPPL).⁴¹ In this T2DM+ cohort, 27 with FMD data also had a diagnosis of CAD (defined as documented prior MI, PTCA/stent, CABG, or >70% stenosis in any vessel by coronary angiography). Both cohorts were recruited from the same neighborhood surrounding CUMC. Combining the two cohorts allowed us to examine a group of 103 individuals with CAD, 52 T2DM+ and 51 T2DM–.

Laboratory

Total cholesterol (TC), triglyceride (TG), HDL-C, and glucose were measured using standard enzymatic techniques on a Hitachi 912 chemistry analyzer.⁴² LDL-C levels were calculated using the Friedewald method.⁴³ CRP levels in the DMPPL cohort were measured using a commercially available Elisa kit (Diagnosis System Laboratories, Inc. Webster, TX) in the Biomarkers Laboratory of the Irving Institute for Clinical and Translational Research (IICTR) at CUMC. CRP in the NOMAS cohort was measured using a BN-II nephelometer (Dade-Behring, Deerfield, IL) in the Center for Advanced Laboratory Medicine at CUMC. CBC, metabolic panel, and total glycohemoglobin were measured on fasting samples by the CUMC clinical laboratory reference range (5.1–8.5%).

Assessment of endothelial function

Arterial endothelial function was non-invasively assessed by FMD, which is the change in brachial artery diameter after regional ischemia. High resolution B-Mode ultrasonography was used to measure FMD.²² All of the studies were analyzed by one reader blinded to the subject's clinical status. After a 12-hour fast, no smoking for 12 hours, and no alcohol intake for three days, individuals were examined in a dark, temperature-controlled, quiet room after 20 minutes of rest. Brachial artery FMD was assessed using a 15-MHz linear array transducer (Agilent 5500, Andover, Mass.). The vessel was imaged above the antecubital fossa in the longitudinal plane. FMD was measured as the dilatory response to reactive hyperemia induced by inflation of a BP cuff on the forearm to suprasystolic levels for 3 minutes. One minute after cuff deflation, the brachial artery diameter was re-measured. Continuous image recording was performed on S-VHS tapes for 30 seconds before and 90 seconds after cuff deflation. The arterial diameter was measured using a digital caliper on the image at a comparable site at baseline and after cuff release. FMD was expressed as percent change = $100 \times [\text{brachial artery diameter at peak hyperemia} - \text{diameter at rest}] / \text{brachial artery diameter at rest}$. Three measurements were averaged at baseline and after cuff deflation, and the averages were used in the analysis. The intra- and inter-observer variability on a sample of 15 subjects were 1.3% and 2.7% respectively.⁴⁴

Statistics

All data were analyzed using SAS software (v 9.1). Data are reported as means $\pm$ standard deviations, except in Figure 1 where standard errors are reported. Triglyceride levels, which were not normally distributed, are summarized by medians and interquartile ranges (IQR). Group comparisons of continuous variables were by unpaired t-tests; triglyceride levels were log transformed in order to make the distributions normal prior to t-tests. The relationships between FMD and other confounding factors were analyzed by multiple regression in order to study the independent effects of multiple factors.

RESULTS

We first investigated the validity of combining the two cohorts. While the methodology for determining FMD was the same for the two cohorts, with the same physiology laboratory and the same reader used for both, the possibility existed that the cohorts differed in some way. The cohorts were different in age with the NOMAS population older (72 ± 8 vs. 60 ± 7 yrs, $P < 0.001$); they also differed in sex ratio (females 52% in NOMAS and 19% in DMPPL). In subsequent analyses, therefore, we included cohort (NOMAS vs. DMPPL) as a factor to account for any difference between the cohorts, along with other covariates (sex, age, BMI, ethnicity, hypertension, lipid levels) in multiple regression models. Statin treatment had the same prevalence in the two groups (27 T2DM+ and 27 T2DM-). The prevalence of hypertension was high in both groups (36.5% in T2DM+ and 47% in T2DM-).

Table 1 presents basic characteristics and lipid profiles in subjects with and without T2DM. As expected, fasting glucose levels were higher in T2DM+ subjects than in T2DM- subjects (174 ± 64 vs. 89 ± 12 mg/dl, $P < 0.0001$). Glycohemoglobin levels were available in the 27 T2DM+ and CAD+ subjects recruited from the DMPPL study. The levels were 11.9 ± 3.1 with a range from 6.8 to 18. Twenty-three of these 27 subjects were on hypoglycemic agents (sulfonylureas-13, metformin-13, insulin-6, acarbose-1, resulin-3, and troglitazone-1). We also observed lower HDL-C levels (35 ± 12.2 vs. 44 ± 11.7 mg/dl, $P < 0.0001$) and higher hsCRP levels (9.1 ± 9.3 vs. 5.3 ± 7.1 ng/ml, $P = 0.05$) in T2DM+ subjects. Median triglyceride levels were nominally higher in T2DM+ (135 mg/dl, 101 – 159 mg/dl IQR) than in T2DM- subjects (108 mg/dl, 77 – 163 IQR), but this difference was not significant ($p = 0.17$) by t-test on log-transformed data.

Figure 1 shows FMD in the two groups. The 52 T2DM+ subjects with CAD had a mean FMD of $3.9 \pm 3.2\%$, while the 51 T2DM- with CAD had a mean FMD of $5.5 \pm 4.0\%$ ($P < 0.03$). In a preliminary multiple regression model, study cohort (NOMAS vs. DMPPL) and several of the variables in Table 1 (sex, race, smoking, lipid levels, systolic blood pressure, and hsCRP levels) were all non-significant. In particular, HDL-C and hsCRP, the two variables that were significantly different between T2DM+ and T2DM- (Table 1) showed no relationship to FMD in the multiple regression model. However, two other variables from Table 1, age ($P < 0.05$) and BMI ($P < 0.06$) were potential confounders, and they were retained in the final model. Table 2 shows that after adjusting for the study cohort, age and BMI, FMD remained lower in T2DM+ compared to T2DM- subjects (difference -1.99% , $P = 0.026$).

DISCUSSION

T2DM and CAD are both known to affect endothelial function, and many studies have examined the association between either CAD²⁶ or T2DM^{19,20} and endothelial function by measuring FMD. Neunteufl et al.²⁶ examined FMD in 74 subjects without T2DM and found that subjects with CAD showed markedly impaired FMD compared to the non-CAD group. FMD has also been shown to detect the severity of CAD in various studies.^{28,29} Wu et al. found that FMD was associated with the presence and extent of coronary disease assessed by stress thallium imaging.²⁸ Rossi et al. prospectively examined 840 healthy non-obese, postmenopausal women and measured FMD. After a 4-year follow-up they found 102 women who developed T2DM; there was a significant increase in the relative risk of diabetes with each unit decrease of baseline FMD.¹⁵ In a large cohort from the HOORN study ($n = 650$),⁴⁵ investigators found that presence of T2DM ($n = 269$) was independently associated with impaired endothelium-dependent FMD; impaired glucose tolerance ($n = 135$) was not associated with FMD. In contrast, Su et al. found that FMD decreased in a stepwise fashion across the spectrum of impaired fasting glucose, glucose intolerance, and T2DM in people without CAD.⁴⁶

There have been only two studies, however, that compared FMD in subjects with both T2DM and CAD to subjects with only CAD,^{36,35} and those two studies produced conflicting results. Kirma et al.³⁶ examined a Turkish cohort of 150 patients with CAD, of whom 42 had T2DM. Similar to our findings, they observed that the subjects with both CAD and T2DM had lower FMD than subjects with CAD but no T2DM. In a stepwise multiple regression analysis, these authors found that age and the presence of T2DM were independent predictors of lower FMD. In our study as well, age was a potential confounder. After adjusting for both age and BMI, we found that FMD remained lower in T2DM+ compared to T2DM- subjects. Bhargava et al.³⁵ examined FMD in 198 Indian subjects divided into four groups; they confirmed prior findings that, in the absence of CAD, FMD is significantly impaired in patients with T2DM compared to subjects without T2DM.

However, in contrast to our findings, they observed a similar degree of ED in subjects with T2DM and CAD compared with subjects who only had CAD. In reviewing the study by Bhargava et. al., we did not find any clear reason for the different outcome. However, FMD was significantly lower in their subjects with both T2DM and CAD compared to subjects with T2DM and no CAD; the group with CAD but no T2DM had an FMD between the latter two groups that was not significantly different from either. This stepwise gradient in FMD lowering from no T2DM and no CAD, to T2DM without CAD, to CAD without T2DM, and finally to both T2DM and CAD, is not markedly different from our results, which only pertain to the last two groups in the Bhargava paper. We would note, however, that the population studied by Bhargava et. al. (Asian Indians) was different from the tri-ethnic population that we investigated.

Why would individuals with both T2DM and CAD have greater ED than individuals with only CAD? One possibility is that people with both CAD and T2DM have a greater number of other factors that are associated with reduced FMD, such as lower HDL-C⁴⁷, higher TG levels⁴⁸, and more hypertension⁴⁹, than people with only CAD. In the present study, HDL-C was lower, and TG levels tended to be higher, in the group with T2DM. On the other hand, both systolic and diastolic blood pressures were slightly but not significantly lower in the T2DM+ than in the T2DM- subjects, consistent with a somewhat lower prevalence of diagnosed hypertension in the T2DM+ group. Smoking status has been shown to affect endothelial function,⁵⁰ and our study included similar numbers of individuals with smoking history in each group. Importantly, when these and other baseline demographic and biochemical data were included in a model to explain the association between T2DM and FMD, only age and BMI were seen to be related to FMD besides the presence of T2DM.

CRP is an acute phase reactant and serum concentrations of hsCRP may be indicative of the presence of inflammation.⁵¹ Whether elevated hsCRP is a marker of a pro-inflammatory state or plays a pathologic role in the development of CVD or T2DM is unclear.⁵² Vitale et. al.⁵³ found a significant correlation between plasma hsCRP levels and endothelial function, suggesting a correlation between inflammation and the integrity of the endothelium. In that study, optimal medical therapy for CAD reduced CRP levels along with a parallel improvement in endothelial function. In our study, hsCRP levels were significantly higher in the T2DM+ group compared with the T2DM- group. However, hsCRP levels were not correlated with FMD within each group, and the difference in FMD between the two groups remained essentially unchanged after adjusting for hsCRP levels. We did not measure inflammatory cytokines in this study; CRP is considered by some to be a representative, if not the strongest marker of CVD risk among the family of inflammatory markers^{46,54} We did not determine plasma levels of soluble adhesion molecules⁶. Both families of molecules are typically elevated in people with T2DM and in individuals with CVD. The value of soluble adhesion molecules for predicting future CVD events, has varied by study⁶.

One obvious difference in the group with both T2DM and CAD compared with the group that only had CAD was the presence of hyperglycemia in the former. Acute hyperglycemia can reduce FMD in normal subjects^{55,56}, which is reversed by concomitant administration of vitamin C⁵⁷ or a combination of vitamins C and E⁵⁶, suggesting a role for oxidative stress in this phenomenon. Evidence that chronic mild hyperglycemia can have detrimental effects on EF comes from the Northern Manhattan Study, in which fasting glucose levels were linearly and inversely related to FMD in subjects without diabetes.⁴⁴ Su et al reported a similar relationship between glycemia and FMD in subjects without CAD.⁴⁶ Additionally, a single oral challenge of advanced glycation end products reduced FMD in both normal and T2DM subjects.⁵⁸ Several groups have studied the effects of glucose lowering therapies on FMD in patients with T2DM; most, but not all, of the studies show that improved glucose

control is associated with improved endothelial function. It is not clear from those studies whether there are differences across classes of agents.^{59–64}

Studies of the effect of intensive glucose lowering on cardiovascular outcomes have produced mixed outcomes. The United Kingdom Diabetes Study showed a trend toward reduced events with either insulin or sulfonylurea therapy,⁶⁵ and a significant reduction in events with metformin treatment.⁶⁶ The Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study demonstrated long-term reductions in mortality after intensive insulin therapy post-myocardial infarction.⁶⁷ Most recently, three major clinical trials, Action to Control Cardiovascular Risk in Diabetes (ACCORD)⁶⁸, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE)⁶⁹, and the study of glucose control and vascular complications in veterans with type 2 diabetes (VADT)⁷⁰ all failed to demonstrate reduced cardiovascular events in patients with T2DM treated to lower HbA1c levels. These results suggest that markers other than glycemia may be more useful in designing new and more intensive approaches to reducing CVD in patients with T2DM. Whether changes in FMD can be used as such a measure of treatment efficacy remains to be determined.

Our study had some limitations: We did not know the angiographic severity of CAD in one of our cohorts, the duration of diabetes, or the specific type of treatment regimens for T2DM that our subjects were receiving. In addition, we did not include a group of participants with DM and no CAD. Also, our study had relatively small numbers; it may have been underpowered to detect some associations with potential cofounders, including hsCRP.

SUMMARY

It is well known that individuals with CAD have low FMD, probably related to the multiple risk factors that contributed to their CAD. In this study, we showed that presence of T2DM is associated with additional negative effects on EF even in the presence of CAD. This could help explain why patients with T2DM and CAD have a worse prognosis, both in terms of early and late survival.^{37,38}

Acknowledgments

This manuscript is dedicated to the memory of Dr. Catherine Tuck (1962–2001) who designed and conducted the postprandial lipemia study in T2DM⁴¹, the source of the second cohort for the present study.

This study was funded by grants from the NIH/NINDS (R27 29993, R01 48134), NIH, NHLBI - JDF: P01 HL 57217; NIH, NCRR: M01 RR00645-25; and T32HL07343. The authors also thank, for their clinical and technical assistance, the Columbia University Echocardiography Research Laboratory, and the staff of the following units of the Irving Institute for Clinical and Translational Research: Clinical Research Center, Biomarkers Laboratory, and the Bionutrition Unit.

References

1. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. *Diabetes Care* 2002;25:1129–1134. [PubMed: 12087009]
2. Expert Panel on Detection EaToHBCiA. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). *JAMA* 2001;285:2486–2497. [PubMed: 11368702]
3. Haffner SM, Lehto S, Ronnema T, et al. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;339:229–234. [PubMed: 9673301]

4. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. *Journal of Clinical Investigation* 1991;87:432–438. [PubMed: 1991829]
5. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. *J Clin Endocrinol Metab* 2009;94:3171–3182. [PubMed: 19509100]
6. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. *Atherosclerosis* 2003;170:191–203. [PubMed: 14612198]
7. Anderson TJ, Gerhard MD, Meredith IT, et al. Systemic nature of endothelial dysfunction in atherosclerosis. *Am J Cardio* 1995;75:71B–74B.
8. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. *J Am Coll Cardiol* 1990;16:349–356. [PubMed: 2115539]
9. Widlansky ME, Gokce N, Keaney JF jr, et al. The clinical implications of endothelial dysfunction. *J Am Coll Cardiology* 2003;42:1149–1160.
10. Celermajer DS, Sorensen KE, Bull C, et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. *J Am Coll Cardiol* 1994;24:1468–1474. [PubMed: 7930277]
11. Shechter M, Issachar A, Marai I, et al. Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. *Int J Cardiol*. 2008
12. Reddy KG, Nair RN, Sheehan HM, et al. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. *Journal of the American College of Cardiology* 1994;23:833–843. [PubMed: 8106687]
13. Reaven GM. Role of insulin resistance in human disease. *Diabetes* 1988;37:1595–1607. [PubMed: 3056758]
14. Diamant M, Tushuizen M. The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD. *Current Diabetes Reports* 2006;6:279–286. [PubMed: 16879779]
15. Rossi R, Cioni E, Nuzzo A, et al. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. *Diabetes Care* 2005;28:702–707. [PubMed: 15735211]
16. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. *Circulation* 1993;90:1109–1110.
17. Jarvisalo MJ, Raitakari M, Toikka JO, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. *Circulation* 2004;109:1750–1755. [PubMed: 15023875]
18. Meeking DR, Cummings MH, Thorne S, et al. Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria. *Diabet Med* 1999;16:841–847. [PubMed: 10547211]
19. Yu HI, Sheu WH, Lai CJ, et al. Endothelial dysfunction in type 2 diabetes mellitus subjects with peripheral artery disease. *Int J Cardiol* 2001;78:19–25. [PubMed: 11259809]
20. Green DJ, Maiorana AJ, Tschakovsky ME, et al. Relationship between changes in brachial artery flow-mediated dilation and basal release of nitric oxide in subjects with Type 2 diabetes. *Am J Physiol Heart Circ Physiol* 2006;291:H1193–H1199. [PubMed: 16565307]
21. Adams MR. Clinical assessment of endothelial function. *Endothelium* 2006;13:367–374. [PubMed: 17169769]
22. Correti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *Journal of the American College of Cardiology* 2002;39:257–265. [PubMed: 11788217]
23. Djaberi R, Beishuizen ED, Pereira AM, et al. Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. *Diabetologia* 2008;51:1581–1593. [PubMed: 18607561]

24. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. *Journal of the American College of Cardiology* 1995;26:1235–1241. [PubMed: 7594037]
25. Takase B, Hamabe A, Satomura K, et al. Close relationship between the vasodilator to acetylcholine in the brachial and coronary artery in suspected coronary artery disease. *Int J Cardiol* 2005;105:58–66. [PubMed: 16207546]
26. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of CAD. *Atherosclerosis* 1997;129:111–118. [PubMed: 9069525]
27. Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. *Am Journal Cardiology* 1996;78:1210–1214.
28. Wu WC, Sharma SC, Choudhary G, et al. Flow-mediated vasodilation predicts the presence and extent of coronary artery disease assessed by stress thallium imaging. *J Nucl Cardiol* 2005;12:538–544. [PubMed: 16171713]
29. Amir O, Jaffe R, Shiran A, et al. Brachial reactivity and extent of coronary artery disease in patients with first ST-elevation acute myocardial infarction. *Am J Cardiol* 2006;98:754–757. [PubMed: 16950178]
30. Yeboah J, Crouse JR, Hsu FC, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. *Circulation* 2007;115:2390–2397. [PubMed: 17452608]
31. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study. The Multi-Ethnic Study of Atherosclerosis. *Circulation* 2009;120:502–509. [PubMed: 19635967]
32. Karatzis EN, Ikonomidis I, Vamvakou GD, et al. Long-term prognostic role of flow-mediated dilation of the brachial artery after acute coronary syndromes without ST elevation. *Am J Cardiol* 2006;98:1424–1428. [PubMed: 17126643]
33. Kitta Y, Nakamura T, Kodama Y, et al. Endothelial vasomotor dysfunction in the brachial artery is associated with late in-stent coronary restenosis. *J Am Coll Cardiol* 2005;46:648–655. [PubMed: 16098430]
34. Akcakoyun M, Kargin R, Tanalp AC, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events and restenosis in patients undergoing coronary stent implantation: a prospective study. *Coron Artery Dis* 2008;19:337–343. [PubMed: 18607171]
35. Bhargava K, Hansa G, Bansal M, et al. Endothelium dependent braquial artery flow mediated vasodilation in patients with diabetes mellitus with and without coronary artery disease. *JAPI* 2003;51:355–358. [PubMed: 12723648]
36. Kirma C, Akcakoyun M, Esen AM, et al. Relationship between endothelial function and coronary risk factors in patients with stable coronary artery disease. *Circ J* 2007;71:698–702. [PubMed: 17456994]
37. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction: The FINMONICA Myocardial Infarction Register Study Group. *Diabetes Care* 1998;21:69–75. [PubMed: 9538972]
38. Sprafka JM, Burke GL, Folsom AR, et al. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey. *Diabetes Care* 1991;14:537–543. [PubMed: 1914792]
39. Sacco RL, Boden-Albala B, Abel G, et al. Race-ethnic disparities in the impact of stroke risk factors: the Northern Manhattan stroke study. *Stroke* 2001;32:1725–1731. [PubMed: 11486097]
40. Pulerwitz T, Grahame-Clarke C, Rodriguez CJ, et al. Association of increased body mass index and impaired endothelial function among Hispanic women. *Am J Cardiol* 2006;97:68–70. [PubMed: 16377286]
41. Reyes-Soffer G, Holleran S, Karmally W, et al. Measures of postprandial lipoproteins are not associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus. *Journal of Lipid Research*. 2009

42. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPAR agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. *JCI* 2005;1323–1332. [PubMed: 15841215]
43. Friedewald WT, Levy RI, Drederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative centrifuge. *Clin Chem* 1972;18:499–502. [PubMed: 4337382]
44. Rodriguez CJ, Miyake Y, Grahame-Clarke C, et al. Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. *Am Journal Cardiology* 2005;96:1273–1277.
45. Henry RM, Ferreira I, Kostense PJ, et al. Type II diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not. *Arteriosclerosis* 2004;174:49–56.
46. Su Y, Liu X-M, Sun Y-M, et al. Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus. *American Journal Cardiology* 2008;102:497–498.
47. Li XP, Zhao SP, Zhang XY, et al. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. *Int J Cardiol* 2000;31:231–236. [PubMed: 10841964]
48. Maggi FM, Raselli S, Grigore L, et al. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. *J Clin Endocrinol Metab* 2004;89:2946–2950. [PubMed: 15181082]
49. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: methods of assessment and application to hypertension. *Curr Pharm Des* 2009;10:3591–3605. [PubMed: 15579056]
50. Tanriverdi H, Evrengul H, Kuru O, et al. Cigarette smoking induced oxidative stress may impair endothelial function and coronary blood flow in angiographically normal coronary arteries. *Circulation* 2006;70:593–599.
51. Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. *Int J Cardiol* 2006;106:291–297. [PubMed: 16337036]
52. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: A causal factor? *Cardiovasc Res* 2006;71:30–39. [PubMed: 16624260]
53. Vitale C, Cerquetani E, Wajngarten M, et al. In patients with coronary artery disease endothelial function is associated with plasma levels of C-reactive protein and is improved by optimal medical therapy. *Ital Heart J* 2003;4:627–632. [PubMed: 14635381]
54. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA* 2007;297:611–619. [PubMed: 17299196]
55. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. *Circulation* 1998;97:1695–1701. [PubMed: 9591763]
56. Title LM, Cummings PM, Giddens K, et al. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. *J Am Coll Cardiol* 2000;36:2185–2191. [PubMed: 11127459]
57. Bechman JA, Goldfine AB, Gordon MB, et al. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. *Circulation* 2001;103:1618–1623. [PubMed: 11273987]
58. Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. *Diabetes Care* 2007;30:2579–2582. [PubMed: 17496238]
59. Antoniadou C, Tousoulis D, Tountas C, et al. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis. the effects of vitamin C. *Diabet Med* 2004;21:552–558. [PubMed: 15154938]
60. Vehkavaara S, Makimattila S, Schienzka A, et al. Insulin therapy improves endothelial function in type 2 diabetes. *Artheroscler Thromb Vasc Biol* 2000;20:545–550.
61. Martens FM, Visseren FL, de Koning E, et al. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. *Cardiovasc Pharmacol* 2005;46:773–778.
62. Kelly AS, Thelen AM, Kaiser DR, et al. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. *Vasc Med* 2007;12:311–318. [PubMed: 18048467]

63. Manzella D, Grella R, Abbatecola AM, et al. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. *Diabetes Care* 2005;28:366–371. [PubMed: 15677794]
64. Bagg W, Whailey GA, Gamble G, et al. Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. *Intern Med J* 2001;31:322–328. [PubMed: 11529585]
65. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:837–853. [PubMed: 9742976]
66. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;352:854–865. [PubMed: 9742977]
67. DIGAMI - Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction- Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. *BMJ* 1997;314:1512–1515. [PubMed: 9169397]
68. Miller ME, Byington BP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545–2559. [PubMed: 18539917]
69. Patel A, MacMahon S, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560–2572. [PubMed: 18539916]
70. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *New Engl J Med* 2009;360:129–139. [PubMed: 19092145]

Figure 1.

Subjects with both CAD and T2DM have lower FMD than subjects with only CAD: Percent flow mediated dilation was measured in 52 participants with CAD and T2DM and in 51 participants with CAD but without T2DM. The data are presented as means and SEs of the percent change from baseline in brachial artery diameter after 3 min local ischemia. These data were not adjusted for any covariates or potential confounders.

Table 1

Baseline Characteristics of Each Group

Characteristics	CAD+T2DM+	CAD+T2DM-	Comparisons (p-values)
	N=52 Mean $\pm$ SD	N=51 Mean $\pm$ SD	
Age (years)	66 $\pm$ 9.6	69 $\pm$ 8.9	NS
BMI (kg/m ²)	31 $\pm$ 4.7	29 $\pm$ 6.0	NS
SBP (mmHg)	137 $\pm$ 21.6	143 $\pm$ 20.5	NS
DBP (mmHg)	78 $\pm$ 13	85 $\pm$ 10	NS
TC (mmol/L)	5 $\pm$ 1.1	4.9 $\pm$ 1.1	NS
LDL C (mmol/L)	3.2 $\pm$ 0.7	3.1 $\pm$ 0.9	NS
HDL C (mmol/L)	0.9 $\pm$ 0.3	1.1 $\pm$ 0.3	0.003
TG (mmol/L)*	1.5 (1.1–1.8)	1.2(0.9–1.8)	NS
Glucose (mmol/L)	9.7 $\pm$ 3.6	4.94 $\pm$ 0.7	<0.0001
CRP (ng/ml)	9.1 $\pm$ 9.3	5.3 $\pm$ 7.1	0.05
Males	65	53	NS
Ethnicity (%)			
Black	10	16	NS
Hispanic	63	59	NS
White	27	25	NS
Cigarette Smoke (%)	50	63	NS
Use Lipid Medications (%)	54	47	NS

BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: total cholesterol, LDL C: low density lipoprotein cholesterol, HDL C: high density lipoprotein cholesterol, TG: triglycerides, CRP: C-reactive protein.

* Median and interquartile range are shown for TG.

Table 2

FMD is significantly lower in CAD with T2DM compared with CAD without T2DM after Adjusting for Age, BMI and Study Cohort.

Variable	Regression Coefficient Estimate	SE	p-Value
T2DM	– 1.99	0.88	0.026
Age	– 0.09	0.04	0.042
BMI	– 0.13	0.07	0.055
Cohort	0.64	1.13	0.57

FMD was 1.99% lower in subjects with both T2DM and CAD compared to subjects with only CAD, even after adjusting for age and BMI, which were also independently associated with lower FMDs, and cohort, which was not significantly related to FMD. Each year of increasing age was associated with a reduction of 0.09% in FMD, and each unit of BMI with a reduction of 0.13% in FMD.